New impetus for a rare form of liver cancer

The cells of cHCC/CCA exhibit features of both forms of cancer. This rare type of cHCC/CCA is considered very aggressive and responds extremely poorly to current treatments.

To identify potential targets for new therapies, a team led by Mathias Heikenwalder of the German Center for Cancer Research and Eithan Galun of the Hebrew University of Jerusalem searched for the cellular origin of these tumors. . The researchers conducted their study in mice that had been genetically engineered to develop chronic hepatitis and hepatocellular carcinoma at an older age, and then also developed cHCC/ CCA. The molecular profile of the cHCC/CCA tumor cells in these animals largely matches that of the human cHCC/CCA cells.

New insights into liver cancer

The German-Israeli research team found that cHCC/CCA develops from precursors of degraded hepatocytes. In contrast, hepatocellular carcinoma most likely arises from damaged mature liver cells.


In cHCC/CCA cells, genes of the proinflammatory signaling pathway interleukin 6 (IL-6) are particularly active. The source of IL-6 that activates this signaling pathway is senescent immune cells. The hallmark of cellular aging, which scientists call “aging,” is the release of a whole mix of proinflammatory signaling molecules, of which IL-6 plays a key role.

Blocking IL-6 activity with specific antibodies reduced both the number and size of cHCC/CCA tumors in mice. An agent that promotes senescent cells to undergo apoptosis, thereby drying up the source of IL-6, also inhibits cHCC/CCA growth.

Today, the most effective therapy for cHCC/CCA is surgical removal of the tumors. It is only successful if the cancer is detected at a very early stage. Mathias Heikenwalder, one of the corresponding authors of the current publication, explains: “Blocking IL-6 or agents that kill senescent IL-6-producing cells could be further tested as promising treatments against this type of cancer,” explains Mathias Heikenwalder, one of the corresponding authors of the current publication. He adds: “There is increasing evidence that tumors that are actually diagnosed as hepatocellular carcinoma also contain a cellular fraction of cHCC/CCA. Potential therapy against cHCC/CCA may also be beneficial for some patients with hepatocellular carcinoma.”

Source: Eurekalert

Source link


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button
Immediate Peak